EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Resveratrol as a Novel Therapeutic Approach for Diabetic Retinopathy: Molecular Mechanisms, Clinical Potential, and Future Challenges

Snježana Kaštelan iD, Suzana Konjevoda iD, Ana Sarić, Iris Urlić, Ivana Lovrić iD, Samir Čanović, Tomislav Matejić, Ana Šešelja Perišin iD

Molecules · 04.08.2025 · 30 (15) · 3262

DOI: 10.3390/molecules30153262 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 04.08.2025. Verfasst von Snježana Kaštelan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Clinical Hospital Dubrava, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia. Hauptthemen laut MEDLINE: Resveratrol, Diabetic Retinopathy, Antioxidants. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic retinopathy (DR) is a progressive, multifactorial complication of diabetes and one of the major global causes of visual impairment. Its pathogenesis involves chronic hyperglycaemia-induced oxidative stress, inflammation, mitochondrial dysfunction, neurodegeneration, and pathological angiogenesis, as well as emerging systemic contributors such as gut microbiota dysregulation. While current treatments, including anti-vascular endothelial growth factor (anti-VEGF) agents, corticosteroids, and laser photocoagulation, have shown clinical efficacy, they are largely limited to advanced stages of DR, require repeated invasive procedures, and do not adequately address early neurovascular and metabolic abnormalities. Resveratrol (RSV), a naturally occurring polyphenol, has emerged as a promising candidate due to its potent antioxidant, anti-inflammatory, neuroprotective, and anti-angiogenic properties. This review provides a comprehensive analysis of the molecular mechanisms by which RSV exerts protective effects in DR, including modulation of oxidative stress pathways, suppression of inflammatory cytokines, enhancement of mitochondrial function, promotion of autophagy, and inhibition of pathological neovascularisation. Despite its promising pharmacological profile, the clinical application of RSV is limited by poor aqueous solubility, rapid systemic metabolism, and low ocular bioavailability. Various routes of administration, including intravitreal injection, topical instillation, and oral and sublingual delivery, have been investigated to enhance its therapeutic potential. Recent advances in drug delivery systems, including nanoformulations, liposomal carriers, and sustained-release intravitreal implants, offer potential strategies to address these challenges. This review also explores RSV’s role in combination therapies, its potential as a disease-modifying agent in early-stage DR, and the relevance of personalised medicine approaches guided by metabolic and genetic factors. Overall, the review highlights the therapeutic potential and the key translational challenges in positioning RSV as a multi-targeted treatment strategy for DR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ResveratrolDiabetic RetinopathyAntioxidantsHumansAnimalsOxidative Stress

Stichwörter der Autor:innen

angiogenesisautophagydiabetic retinopathydrug delivery systemsgut-retina axisinflammationmitochondrial dysfunctionneuroprotectionoxidative stressresveratrol

Substanzen

ResveratrolAntioxidants

Autor:innen und Institutionen

  • Department of Ophthalmology, Clinical Hospital Dubrava, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
  • Department of Ophthalmology, Zadar General Hospital, 23000 Zadar, Croatia.
  • Department of Health Studies, University of Zadar, 23000 Zadar, Croatia.
  • School of Medicine, Catholic University of Croatia, Ilica 242, 10000 Zagreb, Croatia.
  • Department of Ophthalmology, Clinical Hospital Dubrava, 10000 Zagreb, Croatia.
  • Health Center Zagreb East, 10000 Zagreb, Croatia.

ORCID-Profile: Snježana Kaštelan, Suzana Konjevoda, Ivana Lovrić, Ana Šešelja Perišin

Zitieren

APA

Kaštelan, S., Konjevoda, S., Sarić, A., Urlić, I., Lovrić, I., Čanović, S., Matejić, T., & Šešelja Perišin, A. (2025). Resveratrol as a Novel Therapeutic Approach for Diabetic Retinopathy: Molecular Mechanisms, Clinical Potential, and Future Challenges. Molecules, 30(15), 3262. https://doi.org/10.3390/molecules30153262

Vancouver

Kaštelan S, Konjevoda S, Sarić A, Urlić I, Lovrić I, Čanović S, et al. Resveratrol as a Novel Therapeutic Approach for Diabetic Retinopathy: Molecular Mechanisms, Clinical Potential, and Future Challenges. Molecules. 2025;30(15):3262. doi:10.3390/molecules30153262

BibTeX
@article{Katelan2025,
  author = {Kaštelan, Snježana and Konjevoda, Suzana and Sarić, Ana and Urlić, Iris and Lovrić, Ivana and Čanović, Samir and Matejić, Tomislav and Šešelja Perišin, Ana},
  title = {Resveratrol as a Novel Therapeutic Approach for Diabetic Retinopathy: Molecular Mechanisms, Clinical Potential, and Future Challenges},
  journal = {Molecules},
  year = {2025},
  volume = {30},
  number = {15},
  pages = {3262},
  doi = {10.3390/molecules30153262}
}
Kostenlos starten →